Department of War Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program
Open Solicitation Posted
- Solicitation number
- HT9402-27-Q-9101
- Agency
-
Defense Health Agency
Department of Defense
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Place of performance
- San Antonio, Texas 78230, United States
- Points of contact
Notice details come from SAM.gov. Updated .
About this opportunity
The Defense Health Agency, part of the Department of War, seeks quotes under RFQ HT9402-27-Q-9101 for Uniform Formulary Blanket Purchase Agreements and Uniform Formulary Additional Discount Program Agreements covering ophthalmic dry eye and oral testosterone replacement therapy agents, with quotes due December 7, 2026 at 12:00 PM CST. The notice uses no set-aside. A pre-quotation teleconference is scheduled for November 17, 2026, with details in Part 2.4 of the RFQ.
The dry eye class includes Cequa, Eysuvis, Miebo, Tryptyr, Tyrvaya, Verkazia, Vevye, and Xiidra. The oral testosterone class includes Jatenzo, Kyzatrex, and Tlando. The Pharmacy and Therapeutics Committee meets February 3-4, 2027, and will evaluate BPA and ADP quotes as part of its relative cost effectiveness analysis in recommending agent selection and cost share tier classification.
Place of performance is San Antonio, TX 78230. Manufacturers must hold existing Federal Supply Schedule contracts and agree to work with the DoW Prime Vendor Program for Military Treatment Facility and TRICARE Mail Order Pharmacy distribution. Quoted prices must be equal to or lower than FSS, Big 4, and Joint National Contract prices. All quotes must be Trade Agreements Act compliant, and offerors must maintain active SAM registration at time of award. Submissions include a signed Manufacturer Quote Submission Checklist and an NDC Price List in Excel. The per-unit price must be uniform across all package sizes within a dispensing venue unless the government grants a written exception at least 14 days before the quote due date. Quotes remain valid for 180 days. ADP refunds are stated as a percentage of the most recent annual non-FAMP price and are contingent on placement in the generic (Tier 1) or formulary (Tier 2) cost share tier.
Points of contact are Stephanie Erpelding and Julianne Canaley at dha.san-antonio-tx.acquisprrocure.mbx.pharmacysupport@health.mil. The notice carries NAICS 325412, Pharmaceutical Preparation Manufacturing, and PSC 6505, Drugs and Biologicals. The source states no award value or ceiling and names no incumbent.
Notice text
The Department of War (DoW) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoW Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoW Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ.
P&T COMMITTEE MEETING: The following February 2027 drug classes/subclasses will be reviewed:
a. Ophthalmic - Dry Eye
- Cequa
- Eysuvis
- Miebo
- Tryptyr
- Tyrvaya
- Verkazia
- Vevye
- Xiidra
b. Testosterone Replacement Therapy - Orals
- Jatenzo
- Kyzatrex
- Tlando
The RFQ, including UF BPA and UF ADP appendices, are attached herein. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-27-Q-9101. Pre-quotation teleconference is on November 17, 2026. Details are stated in Part 2.4. Pre-Quotation Teleconference.
Files
| File | Type | Posted |
|---|---|---|
| PL - Ophthalmic - Dry Eye.xlsx | XLSX spreadsheet | |
| NDC Price List FAQ Class Review.pdf | ||
| RFQ HT9402-27-Q-9101.pdf | ||
| PL - Testosterone Replacement Therapy - Orals.xlsx | XLSX spreadsheet | |
| FAR 52-225-6-Certificate.pdf | ||
| Feb 2027 PandT Meeting Reporting.xlsx | XLSX spreadsheet |
Similar open opportunities
| Opportunity | Agency | Set-aside | Responses due |
|---|---|---|---|
| Fluconazole tablets and 1 more item | Medical Supply Chain | No set-aside | |
| Clotrimazole cream | Medical Supply Chain | No set-aside | |
| Ropinirole ophthalmic | Medical Supply Chain | No set-aside | |
| Speculum, ear | Medical Supply Chain | No set-aside | |
| Sumatriptan succinate and 1 more item | Medical Supply Chain | No set-aside |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity